Summary of Roivant Sciences Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Date**: March 11, 2026 - **Key Speaker**: Matt Gline, CEO Core Industry Insights - **Transformative Period**: Roivant is experiencing a transformative phase, focusing on drug development and indication selection, with a strong pipeline of products ready for launch and data release [6][8] - **Upcoming Launches**: The company anticipates launching a product for dermatomyositis by the end of September 2026, following the acceptance of their NDA with priority review [7] Key Products and Programs - **Brepocitinib**: - Targeting dermatomyositis, an orphan inflammatory disease with high unmet need. The current patient population in the U.S. is estimated at 40,000, with 75% on first-line therapies [24][25] - The drug is positioned as a significant alternative to existing treatments, particularly for patients currently on high-dose corticosteroids [29] - The launch strategy involves building a patient support organization and a qualified field force to ensure effective adoption [20][31] - **Other Indications**: - **Cutaneous Sarcoidosis**: A pivotal program is set to begin, with promising phase 2 results showing a significant improvement in disease activity [32][34] - **Non-Infectious Uveitis (NIU)**: Data from pivotal studies is expected in the second half of 2026, with a patient population of approximately 70,000 [46][48] Market Context and Competitive Landscape - **Market Opportunity**: The company is focusing on orphan diseases where there is a high unmet need, allowing for a different risk-benefit analysis compared to more common conditions [42] - **Safety Profile**: Brepocitinib, while a JAK inhibitor, is expected to have a favorable safety profile in the context of orphan diseases, where the cost-benefit trade-off is more favorable [44] Future Directions - **Expansion of Indications**: Roivant is exploring additional indications for brepocitinib, including pulmonary sarcoidosis and other severe inflammatory conditions [50][52] - **Immunovant Developments**: The company is also developing FcRn inhibitors, with significant upcoming data releases for conditions like cutaneous lupus and treatment-refractory rheumatoid arthritis [86][88] Financial and Operational Strategy - **R&D Focus**: The company emphasizes a rigorous economic approach to R&D, aiming to maximize value from clinical trials and partnerships [15][16] - **Commercial Strategy**: Roivant plans to leverage learnings from other biotech companies to ensure successful commercial launches, particularly in orphan indications [30][31] Conclusion Roivant Sciences is positioned at a pivotal moment with multiple product launches and data readouts on the horizon, focusing on high unmet needs in orphan diseases. The company's strategic approach to drug development and commercialization aims to capitalize on its innovative pipeline and market opportunities.

Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [6][7] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][8] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The potential market for cutaneous sarcoidosis is estimated to be slightly smaller than dermatomyositis, with around 40,000 eligible patients [79] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase 2 study to inform the design of the phase 3 trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, highlighting its potential to address significant patient needs [25][36] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including other forms of sarcoidosis and related conditions [35][36] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about expanding brepocitinib's development, particularly in large orphan markets with high unmet needs [35][36] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - There were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Pricing has not been finalized, but it is expected to be positioned within the orphan drug pricing envelope [48][50] Question: What are the expectations for the phase 3 trial design? - The phase 3 trial is expected to be similar in size to the phase 2 trial, with final details to be discussed with the FDA [58][79] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [83][84]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability and pursue additional opportunities [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase IIb study for 1402 in D2T-RA has fully enrolled [6][7] - The phase II study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][28] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The company estimates around 40,000 eligible patients for cutaneous sarcoidosis, indicating a significant market opportunity [77] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase II study to inform the design of the phase III trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase II data for brepocitinib, highlighting its potential to address significant patient needs in various indications [25][36] - The company anticipates a catalyst-rich period ahead, with multiple NDA and BLA filings expected in the coming years [31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including potential expansion into other forms of sarcoidosis [36][84] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about further development and is considering additional indications, emphasizing the strong data supporting brepocitinib's efficacy [35] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - Management noted that there were some significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Management has not finalized pricing but indicated it will be positioned as an orphan-priced drug, with considerations based on existing therapies [48][50] Question: What is the expected size and design of the phase III study? - Management indicated that the phase III study would likely be similar in size to the DM trial, with final details to be determined after discussions with the FDA [59][79] Question: What percentage of patients in the Brepo study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and around 30% had other organ involvement, primarily ocular [84]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [27][28] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [28] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [5][6] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [6][25] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [23][34] - The market opportunity for cutaneous sarcoidosis is estimated at around 40,000 eligible patients, which is slightly smaller than the dermatomyositis opportunity [75] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, including other forms of sarcoidosis [33][94] - The company aims to leverage its unique TYK2 and JAK1 inhibition mechanism to explore new therapeutic areas with high unmet needs [93] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, indicating it could be a significant treatment option for patients with cutaneous sarcoidosis [9][23] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [26][27] - The company is preparing for pivotal data readouts in 2027 for its FcRn product, IMVT-1402, which is expected to have best-in-class efficacy [24] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about further development and sees brepocitinib as a strong agent for patient populations in need, with ongoing considerations for other forms of sarcoidosis [33] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - Management noted that there were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42] Question: What are the pricing considerations for brepocitinib? - Pricing has not been finalized, but management indicated it would be positioned as an orphan-priced drug, with considerations based on existing therapies [48] Question: What is the expected size and design of the phase 3 study? - Management indicated that the phase 3 study would likely be similar in size to the dermatomyositis trial, but final details will depend on discussions with the FDA [56][75] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [82]

Core Insights - Roivant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, marking a significant breakthrough in treatment options for this condition [1][2][10] - The company reported a consolidated cash position of approximately $4.5 billion as of December 31, 2025, supporting its financial stability and ongoing development efforts [12][17] Clinical Development - The BEACON study involved 31 patients and demonstrated that brepocitinib 45 mg resulted in a 22.3-point improvement in mean CSAMI-A at Week 16 compared to a 0.7-point improvement in placebo, with statistical significance (Δ21.6, P<0.0001) [3][4][10] - Brepocitinib 45 mg achieved a 100% response rate on multiple endpoints, with 62% of patients reaching functional remission (CSAMI-A <5) compared to 0% in the placebo group [5][6] - The company plans to initiate a Phase 3 study for cutaneous sarcoidosis in 2026, following engagement with the FDA, representing the third pivotal program for brepocitinib [4][8][10] Financial Performance - Research and development expenses increased by $23.8 million to $165.4 million for Q3 2025, driven by program-specific costs and share-based compensation [13][15] - General and administrative expenses rose by $33.5 million to $175.1 million for the same period, primarily due to an impairment loss related to the relocation of the corporate headquarters and increased share-based compensation [16][18] - The company reported a loss from continuing operations of $313.7 million for Q3 2025, compared to a loss of $208.9 million for the same period in 2024 [20][21] Upcoming Milestones - Topline data from Phase 3 studies in non-infectious uveitis are expected in the second half of 2026, along with data from trials for other indications of brepocitinib and IMVT-1402 [4][10][17] - A jury trial in the U.S. Moderna case is scheduled for March 2026, with significant developments anticipated in ongoing litigation [17][10]

Company Overview - Roivant is a biopharmaceutical company focused on improving patient lives by accelerating the development and commercialization of important medicines [3] - The company's pipeline includes several key product candidates such as brepocitinib for autoimmune diseases, IMVT-1402 and batoclimab targeting IgG-mediated autoimmune indications, and mosliciguat for pulmonary hypertension [3] Upcoming Events - Roivant will host a live conference call and webcast on February 6, 2026, at 8:00 a.m. ET to report its financial results for the second quarter ended December 31, 2026, and provide a business update [1][2] Investor Relations - Details for accessing the conference call will be available on Roivant's website, and an archived version of the webcast will be accessible post-event [2]

Summary of Roivant Sciences FY Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: FY Conference Call on January 12, 2026 - **Speaker**: CEO Matt Gline Key Points Company Positioning and Strategy - Roivant is entering a new era with a significantly simplified business model focused on a smaller subset of products, emphasizing clinical execution and pipeline potential [3][4] - The company aims to shape its own destiny with a high priority on delivering results from its clinical programs [3] Financial Strength - Roivant reported a cash balance of **$4.4 billion**, positioning it well for future growth without the need for additional fundraising [5][9] - The company has a strong track record with **12 positive phase III studies** and **8 FDA approvals**, indicating robust past performance and a solid pipeline [9] Clinical Development Highlights - **Brepocitinib**: Positive data for dermatomyositis (DM) with plans to file an NDA by early 2026, marking it as the first novel oral therapeutic for DM [4][5] - **IMVT-1402**: Progressing in pivotal studies for Graves' disease, with expectations for significant disease-modifying benefits [4] - Upcoming data releases include registrational programs for brepocitinib in non-infectious uveitis (NIU) and phase IIb data for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) [6][7] Market Opportunities - The company sees a potential **$15 billion-plus portfolio** across various indications, with significant opportunities in DM, NIU, and Graves' disease [19][70] - Brepocitinib is expected to capture market share from existing therapies, particularly for patients currently on high-dose steroids or IVIG [41][42] Competitive Landscape - Roivant is positioned to be among the first non-prostacyclin novel mechanisms in PH-ILD, competing against established treatments [6][57] - The company is optimistic about the potential for brepocitinib to outperform existing treatments in DM, especially given the enthusiasm from physicians [41][46] Legal and Regulatory Environment - Ongoing litigation with Moderna regarding lipid nanoparticle technology, with a jury trial scheduled for March 2026 [5][60] - The outcome of this case may have implications for other ongoing litigations and the company's overall strategy [62] Future Outlook - Roivant anticipates a transformative next 36 months with multiple commercial launches and pivotal study readouts [11][19] - The company is focused on executing its clinical programs and expanding its pipeline to drive future value [19][29] Unique Business Model - Roivant's model combines talent from various backgrounds, emphasizing creative clinical development and a focus on delivering value to patients [10][30] - The company aims to differentiate itself by maintaining high standards for partnerships and transactions, driven by a focus on profitability [36] Conclusion - Roivant Sciences is positioned for significant growth with a strong financial foundation, a focused pipeline, and a commitment to innovative clinical development. The upcoming years are expected to be pivotal for the company as it seeks to capitalize on its opportunities in the biotech space [19][70]

If You Didn't Buy Roivant in 2025, Now Is the Time J.P. Morgan Healthcare Conference January 12, 2026 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial p ...

Roivant Sciences Investor Day Summary Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 2025 Investor Day held on December 11, 2025 - **Context**: First Investor Day since 2022, highlighting significant progress and future plans [1][4] Key Points and Arguments Business Transformation - Roivant is undergoing a transformation, marking a new decade focused on simplified operations and the development and commercialization of promising programs [5][6] - The company emphasizes a shift from its previous decade, aiming for a more streamlined approach [6] Clinical Execution and Pipeline Opportunities - Roivant has made substantial progress in clinical milestones, with multiple pipeline programs showing potential for blockbuster indications [6][7] - The company has a well-capitalized position with $4.4 billion in cash and cash equivalents, allowing for funding into profitability [7][8] - Roivant has a strong track record with 12 positive phase three studies and eight FDA approvals, with three commercial launches anticipated [8][9] Unique Talent Model - The leadership team is primarily homegrown, fostering a unique organizational culture that emphasizes rapid adaptation and alignment of incentives with project success [9][10] Focus on Execution - Roivant is committed to executing clinical programs effectively, with recent updates indicating accelerated timelines for NDA filings and clinical data readouts [12][13][14] Commercial Opportunities - The company is targeting high-value indications with significant unmet medical needs, particularly in the areas of dermatomyositis (DM), non-infectious uveitis (NIU), and cutaneous sarcoidosis [16][17][18] - The commercial strategy is designed to capitalize on the current biotech landscape, focusing on tractable indications with limited competition [21][22] Specific Programs and Indications Brepocitinib (Brepo) - Brepo is a dual inhibitor of JAK1 and TYK2, with potential applications in DM, NIU, and cutaneous sarcoidosis [25][26] - The NDA filing for DM is expected by early 2026, with significant enthusiasm from the clinical community [12][26] - The NIU program is particularly promising, with a high unmet need and a market of potentially under 200,000 patients [33][34] Non-Infectious Uveitis (NIU) - NIU is a leading cause of blindness among working-age populations, necessitating aggressive treatment strategies [34][35] - The company has observed significant systemic therapy use among NIU patients, indicating a strong market opportunity for new therapies [39][40] Cutaneous Sarcoidosis - Roivant is pursuing cutaneous sarcoidosis as a significant indication, with a small proof-of-concept study underway [48][49] - The potential market includes around 40,000 patients in the U.S., with a high urgency for effective treatments [51][52] Financial Performance and Shareholder Value - Roivant has returned cash to shareholders since going public, increased its cash balance, and doubled its share price [18] - The company has repurchased $1.5 billion of stock since its IPO, with an additional $500 million authorized for buybacks [8][9] Market Context and Future Outlook - The current biotech environment presents unique opportunities for Roivant, with a shift towards successful commercialization of innovative therapies [20][21] - The company is well-positioned to navigate macroeconomic and regulatory changes, with a focus on executing its pipeline effectively [21][22] Conclusion - Roivant Sciences is poised for significant growth with a robust pipeline, strong financial backing, and a commitment to addressing high unmet medical needs in the biotech sector [6][7][8]